Zacks Research Has Negative Outlook for CRL Q1 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at Zacks Research dropped their Q1 2025 earnings per share estimates for shares of Charles River Laboratories International in a research report issued to clients and investors on Tuesday, December 24th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.35 per share for the quarter, down from their prior estimate of $2.42. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.18 per share. Zacks Research also issued estimates for Charles River Laboratories International’s FY2025 earnings at $9.99 EPS, Q1 2026 earnings at $2.75 EPS, Q3 2026 earnings at $2.87 EPS and FY2026 earnings at $11.60 EPS.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period in the prior year, the firm posted $2.72 EPS. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year.

Several other brokerages have also issued reports on CRL. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research note on Monday, November 18th. Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. TD Cowen boosted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Bank of America cut their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, Robert W. Baird decreased their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, September 20th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International has an average rating of “Hold” and an average price target of $214.00.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $186.16 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market capitalization of $9.52 billion, a PE ratio of 23.30, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38. Charles River Laboratories International has a 52-week low of $176.48 and a 52-week high of $275.00. The company has a 50-day simple moving average of $193.06 and a 200 day simple moving average of $201.23.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its position in Charles River Laboratories International by 25.1% in the second quarter. Bank of New York Mellon Corp now owns 480,342 shares of the medical research company’s stock valued at $99,229,000 after purchasing an additional 96,319 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 193 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Charles River Laboratories International by 1.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 206,014 shares of the medical research company’s stock worth $42,558,000 after purchasing an additional 1,970 shares during the period. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Charles River Laboratories International by 41.3% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 1,300 shares of the medical research company’s stock worth $269,000 after purchasing an additional 380 shares during the last quarter. Finally, iA Global Asset Management Inc. bought a new stake in shares of Charles River Laboratories International in the 2nd quarter worth approximately $87,000. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).